The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
began when the first sequence was published, and this forms the basis for …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. …

The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines
and therapeutics will depend on understanding viral immunity. We studied T cell memory …

The CD44 molecule is known to display extensive size heterogeneity, which has been
attributed both to alternative splicing and to differential glycosylation within the extracellular …

SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being
deployed at scale, aiming to generate responses against the virus spike. The scale of the …

The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA.1 …

Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency
use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) …

Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million
infections occurring annually. To gain insight into dengue immunity, we characterized 145 …

A subset of the tumour necrosis factor (TNF) receptor family contain a conserved intracellular
motif, the death domain. Engagement of these receptors by their respective ligands initiates …